Phase 2 N=64 Therapy for Children With Advanced Stage Neuroblastoma
Neuroblastoma
Primary: Overall Response Rate [Complete Response + Very Good Partial Response + Partial Response (CR + VGPR + PR)] — 42 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=34 Bevacizumab, Irinotecan and Temozolomide for Relapsed or Refractory Neuroblastoma
Neuroblastoma
Primary: Overall Responses — 3; 18; 12; 1 Participants
Phase 2 N=112 Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma
Neuroblastoma · Medulloblastoma
Primary: Number of Participants With Related Adverse Events as a Measure of Safety and Tolerability — 45 Participants
N/A N=16 Molecular Guided Therapy for Refractory or Recurrent Neuroblastoma
Neuroblastoma
Primary: Percentage of Participants That Are Able to Meet Feasibility Parameters. — 100 percentage of participants
Phase 2 N=52 Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma
Recurrent Neuroblastoma
Primary: Number of Patients With Unacceptable Dose Limiting Toxicities (DLTs) — 1; 2; 9; 18 participants
Phase 2 N=59 Irinotecan and Temozolomide in Treating Young Patients With Recurrent Neuroblastoma
Neuroblastoma
Primary: Overall Response - Complete Response (CR), Very Good Partial Response (VGPR) and Partial Response (PR) — 5; 3 participants
Phase 2 N=39 hu14.18-Interleukin-2 Fusion Protein in Treating Young Patients With Recurrent or Refractory Neuroblastoma
Neuroblastoma
Primary: Number of Responders (Response Rate) — 0; 5; 13; 18 participants
Phase 2 N=92 ABT-751 in Treating Children With Neuroblastoma That Has Relapsed or Not Responded to Previous Treatment
Disseminated Neuroblastoma · Recurrent Neuroblastoma
Primary: Median Time to Progression as Assessed by Response Evaluation Criteria in Solid Tumors — 45; 42 days
Phase 1 N=18 TPI 287 in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma
Neuroblastoma · Medulloblastoma · Relapse
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 14 participants
Phase 1 N=32 High-Dose 131I-MIBG Therapy Combined With Vincristine and Five Days of Irinotecan for Resistant/Relapsed Neuroblastoma
Neuroblastoma
Primary: Number of Participants With Dose-limiting Toxicity as a Measure of Tolerability — 0; 0 participants with DLT
Phase 2 N=50 N2001-02: I-MIBG With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma
Neuroblastoma
Primary: Response (Complete Response, Very Good Partial Response, and Partial Response) at 60-days Post Stem Cell Infusion — 4; 3 participants
Phase 2 N=15 N2007-01: Ultratrace™ Iobenguane I 131 in Patients With Relapsed/Refractory High-Risk Neuroblastoma
Neuroblastoma
Primary: Maximum Tolerated Dose — 18.6 mCi/kg
Phase 1 N=5 Study of Donor Derived, Multi-virus-specific, Cytotoxic T-Lymphocytes for Relapsed/Refractory Neuroblastoma
Neuroblastoma
Primary: Number of Participants With Immediate and Short Term Toxicity of Infusion Over 8 Weeks — 0; 0; 3 Participants
Phase 2 N=42 Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma
Recurrent B-Cell Childhood Acute Lymphoblastic Leukemia · Recurrent Childhood B-Lymphoblastic Lymphoma
Primary: 3-year Overall Survival Rate of Patients With Relapsed ALL — 94.4; 55.5; 72.63 percentage of participants — p=0.035
Phase 2 N=73 Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma
Ganglioneuroblastoma · Recurrent Neuroblastoma
Primary: Percentage of Randomized Patients Who Are Responders — 5.6; 52.9 Percentage of patients
Phase 1 N=45 MIBG With Dinutuximab +/- Vorinostat
Neuroblastoma
Primary: MTD/RP2D Determination Cohort A — 0; 0; 0 Participants
Phase 3 N=105 Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant in Treating Patients With Neuroblastoma
High Risk Neuroblastoma
Primary: Percentage of Patients Who Experienced a Significant (CTC Grade 3-5) Nonhematologic Toxicity of Interest (Pain, Hypotension, Allergic Reactions, Capillary Leak Syndrome…
Phase 2 N=15 Thalidomide and Temozolomide in Relapsed or Progressive CNS Disease or Neuroblastoma
Central Nervous System Tumor, Pediatric · Neuroblastoma
Primary: Therapy Completion Rate — .40 proportion of participants
Phase 3 N=464 Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma
Neuroblastoma
Primary: Overall Survival (OS) Rates — 99.4; 93.5; 88.4 percentage of participants
Phase 2 N=114 131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat
Neuroblastoma
Primary: Objective Tumor Response After One Course of Therapy — 5; 5; 11 Participants
Phase 1 N=150 Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
Ganglioneuroblastoma · Stage 1 Neuroblastoma · Stage 2 Neuroblastoma
Primary: The Tolerability of BuMel Regimen — 9 participants
Phase 2 N=62 Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma
Pleuropulmonary Blastoma · Recurrent Malignant Peripheral Nerve Sheath Tumor · Recurrent Neuroblastoma
Primary: Objective Response by Response Evaluation Criteria in Solid Tumors Version 1.1 — 0.00; 6.25; 0.00; 0.00 Percent of participants
Phase 1 N=12 Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma
High Risk Neuroblastoma · Recurrent Neuroblastoma · Recurrent Osteosarcoma
Primary: Percent (95% CI) of Participants With Grade 3 or Higher Adverse Events (Dose Finding Cohort) — 71.4; 100 percentage of participants
Phase 2 N=16 Study of Difluoromethylornithine (DFMO) in Combination With Bortezomib for Relapsed or Refractory Neuroblastoma
Neuroblastoma Recurrent
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 2; 1; 3 Participants
Phase 1 N=99 Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
Ganglioneuroblastoma · Localized Resectable Neuroblastoma · Localized Unresectable Neuroblastoma
Primary: Percentage of MIBG Avid Patients Treated With Meta-iodobenxylguanide (MIBG) Labeled With Iodine-131 — 86.8 Percentage of participants
Phase 2 N=31 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Primary Refractory Neuroblastoma in Bone Marrow
Neuroblastoma
Primary: Assess the Activity of High-dose 3F8/GM-CSF
Phase 1 N=21 Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide
Neuroblastoma
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 2; 4; 0; 5 participants
Phase 2 N=19 Study Evaluating Biomarkers In Relapsed/Refractory Pediatric Solid Tumors
Adenocarcinoma · Neoplasms
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs): Part 1 — 4; 5; 3; 7 participants
Phase 2 N=4 High-Dose 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Myeloablative Therapy and Autologous Stem-Cell Transplantation
Neuroblastoma
Primary: Assess the Impact of High-dose 3F8/GM-CSF on Relapse-free Survival
Phase 1 N=65 NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)
Neuroblastoma
Primary: MTD/RP2D Determination A1 — 0; 0; 0; 0 Participants